Virtual acute lymphoblastic leukemia (ALL) eCases illustrate best practices for asparaginase treatment management through the use of concise, interactive clinical scenarios. Cases cover different challenges associated with asparaginase use in pediatric and adolescent/young adult (AYA) patients, and present experts’ recommendations along with data to support decision points throughout the patient’s disease course.
XX AMA PRA Category 1 Credit(s)™
Jul 30, 2018
Jul 30, 2019
- Use of pediatric-inspired protocols for treating ALL in AYAs
- Minimal residual disease testing in AYA patients with ALL
Eunice Wang, MDRoswell Park Cancer Institute
Buffalo, New York, United States
Amro El-Shoury, MDRoswell Park Cancer Institute
Buffalo, New York, United States
This activity is designed to meet the educational needs of hematologists, pediatric hematologists, nurses, physician assistants, nurse practitioners, and other healthcare professional who treat or manage patients with hematologic malignancies.
After successful completion of this educational activity, participants should be able to:
- Discuss the use of asparaginase in the treatment of pediatric and AYA patients with ALL
- Develop optimal strategies to manage adverse events related to the use of asparaginase in ALL, including hypersensitivity reactions
This educational activity is supported by a grant from Shire.
prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
prIME Oncology designates this Enduring material for a maximum of [XX] AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is provided by prIME Oncology.
Method of Participation
Links to the post-test are available on the video player pages.
In order to receive credit, participants must successfully complete the online posttest with 75% or higher.
Disclosure of Relevant Financial Relationships
prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
[SPEAKER NAME] has disclosed ______. S/He has agreed to disclose any /unapproved uses of drugs or products referenced in her/his presentation.
The employees of prIME Oncology have disclosed:
- Ronald Viggiani, MD (medical director content reviewer/planner) – no relevant financial relationships
- Kristin Tomlinson, PhD (scientific content reviewer/planner) – no relevant financial relationships
- Heather Tomlinson, ELS (editorial content reviewer) – no relevant financial relationships
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.